- EMVision Medical Devices (EMV) completes the enrolment of 30 healthy volunteers into its stage one clinical trial for its brain scanning tech
- The company is looking to test its portable EMVision brain scanner device, which obtains images of the human brain using electromagnetic techniques to diagnose and monitor stroke progression
- EMV says its pre-validation phase of the trial has been tracking well, with early indications from trial members showing high-quality, “stable and consistent” signals
- CEO Ron Weinberger says this is an “encouraging” start to the trials, with preparations now underway to activate stage two of the pre-validation phase shortly
- EMVision Medical Devices shares are up 1.69 per cent to $1.50 at 10:22 am AEDT
EMVision Medical Devices (EMV) has completed the enrolment of all 30 healthy volunteers into its stage one clinical trial for its brain scanning technology.
The company is looking to test its portable EMVision brain scanner device, which obtains images of the human brain using electromagnetic techniques to diagnose and monitor stroke progression.
EMV said its pre-validation phase of the clinical trial had been “tracking well”, with each healthy participant at Liverpool Hospital scanned using the EMVision first-generation portable brain scanner alongside an MRI.
Once the full dataset has been received, it will be processed and analysed.
However, the company noted early indications from an engineering review of an initial cohort had already been “promising”, showing high-quality signals that were “stable and consistent”.
The hardware is performing as designed, and the participant data will be used to advance EMVision’s artificial intelligence (AI) algorithms and other imaging techniques.
EMVision CEO Ron Weinberger said this was an encouraging start to the trials.
“Having highly reproducible inputs to our algorithms is a critical first step and a key aim of this phase,” Dr Weinberger said.
“We are excited to shortly move our potentially game-changing technology into the Emergency Department environment to begin generating valuable acute stroke and stroke mimic data.”
Preparations are now underway to enable stage two of the pre-validation phase to shortly be activated.
This second stage will see up to 150 acute stroke and stroke mimic patients enrolled across stroke centres including Liverpool Hospital, Royal Melbourne Hospital and Princess Alexandra Hospital in Brisbane.
EMVision Medical Devices shares were up 1.69 per cent to $1.50 at 10:22 am AEDT.